Zentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results

Zentalis Pharmaceuticals (NASDAQ:ZNTL) issued its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08), FiscalAI reports.

Zentalis Pharmaceuticals Stock Up 4.7%

ZNTL stock traded up $0.12 during midday trading on Thursday, reaching $2.67. 428,202 shares of the company’s stock traded hands, compared to its average volume of 1,321,288. The company has a 50-day simple moving average of $2.59 and a two-hundred day simple moving average of $1.93. Zentalis Pharmaceuticals has a 1-year low of $1.01 and a 1-year high of $3.95. The company has a market cap of $192.91 million, a price-to-earnings ratio of -1.29 and a beta of 1.71.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, insider Vincent Vultaggio sold 29,951 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the transaction, the insider directly owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. The trade was a 16.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Group Walters purchased 6,459,973 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The shares were bought at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the purchase, the insider directly owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. The trade was a 91.63% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders sold 46,617 shares of company stock worth $113,417. Insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of ZNTL. Invesco Ltd. lifted its stake in shares of Zentalis Pharmaceuticals by 8.6% in the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after purchasing an additional 14,961 shares during the period. XTX Topco Ltd boosted its position in shares of Zentalis Pharmaceuticals by 5.1% in the 4th quarter. XTX Topco Ltd now owns 576,707 shares of the company’s stock worth $779,000 after purchasing an additional 28,078 shares during the last quarter. Quadrature Capital Ltd grew its stake in shares of Zentalis Pharmaceuticals by 126.8% during the fourth quarter. Quadrature Capital Ltd now owns 137,568 shares of the company’s stock worth $186,000 after purchasing an additional 76,917 shares during the period. Opaleye Management Inc. grew its stake in shares of Zentalis Pharmaceuticals by 342.6% during the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after purchasing an additional 1,084,356 shares during the period. Finally, ADAR1 Capital Management LLC increased its holdings in Zentalis Pharmaceuticals by 60.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 80,000 shares of the company’s stock valued at $108,000 after purchasing an additional 30,000 shares during the last quarter.

Analyst Upgrades and Downgrades

Separately, Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a research report on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $5.00.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.